Europe · raised · biotech
Big Picture Bio's model correctly predicted 12 of 14 ASCO 2026 Phase 3 oncology trial results before any data emerged.
Big Picture Bio develops a generative world model to forecast cancer drug combination results. The Deep Science Ventures spin-out closed a 2.2 million pound round after posting an 86 percent hit rate on upcoming ASCO 2026 Phase 3 trials.